INTRODUCTION
============

About three quarters of the population of the industrialized western world, occasionally experience low back pain (LBP) in their lifetime, which is one of the commonest causes of activity limitation among the younger age group \[[@R1]\]. Apart from the distress and disability incurred to the patient, it also takes a heavy toll upon the socioeconomic aspect of the society \[[@R2]\]. Its prevalence in Norway has been estimated to be 53 % \[[@R3]\]. Lumbar disc degeneration (LDD) is believed to represent a major cause of LBP \[[@R4],[@R5]\], but a comprehensive definition and insight into its etiology and pathogenesis are still lacking.

Progressive structural failure can trigger an aberrant response of the disc cells, leading to degeneration of the disc \[[@R6]\]. A series of cellular and morphological age related changes occurs in the discs over time \[[@R7]\]. The prevalence of LDD is about 40 % under 30 years and over 90 % in the fifth decade of life \[[@R8]\]. A degenerated disc causing pain is labeled as degenerative disc disease \[[@R6]\] and not all radiologically assessed changes cause pain \[[@R9]\].

Until the beginning of the nineties, etiology was attributed mainly to the environmental influences on the normally aging disc, such as occupational or leisure time physical loading, postural stresses, vibration, injury, driving and smoking \[[@R10]-[@R14]\]. Later, twin studies established a strong familial predisposition and emphasis was laid on major contribution from genetic factors \[[@R15]-[@R18]\]. It is quite likely that the LDD has a multifactorial pathogenesis, also involving gene environment interactions \[[@R19]\].

Genes related to the molecular components of the disc and associated biochemical pathways have been explored as candidate genes for LDD. The extracellular matrix of aggrecan containing gelatinous nucleus and fibro cartilaginous annulus fibrosus is mainly composed of Collagen I and II, with Collagen I predominantly in the annulus and Collagen II in nucleus. Collagens V, VI, IX, XI, XII and XIV also contribute to the matrix though scarcely \[[@R20]\]. Disc degeneration involves dehydration due to fragmentation and eventual loss of aggrecan from the nucleus, causing it to behave non-hydrostatically under load \[[@R21]\]. This leads to disc height reduction and eventually osteoarthritis of apophyseal joints. Aggrecan, also prevents large pro inflammatory molecules from entering into the matrix \[[@R22]\] and with its loss, there is an increased inflow of such molecules which can cause degeneration by enzymatic break down and local inflammation \[[@R23]\]. Associated pain can occur due to sensitization of nerve root by these inflammatory molecules secreted by the cells of a degenerated, herniated disc such as prostaglandin E2, phospholipase A2, MMPs, TNF-α and interleukins \[[@R24],[@R25]\].

Hence all genes coding for the structural proteins of a disc, those involved in inflammation, matrix turnover and degradation are ideal candidates to be analyzed for exploring the role of genetics in disc degeneration. So far significant associations for the polymorphisms of aggrecan (AGC), collagens (COL1A1, COL9A1, COL9A2, COL9A3, COL11A1, COL11A2), vitamin D receptor (VDR), matrix metalloproteinases (MMP2, MMP3, MMP9), interleukins (IL1, IL2, IL18R1, IL18RAP), cyclooxygenase-2 (COX2) and cartilage intermediate layer protein (CILP) have been reported with different pathologic changes of disc degeneration and clinical phenotypes \[[@R26]-[@R44]\]. To our knowledge, the association of these gene candidates has never been tested in a Norwegian LDD cohort.

Osteoarthritis in general, is another morbid condition that has similarities in clinical phenotypes with LDD \[[@R45]\] which involves OA of facet joints. Genes coding for frizzled-related protein (FZRP), calmodulin (CALM1), growth and differentiation factor 5 (GDF5), prostaglandin-endoper-oxidase synthase-2 (PTGS2) and double von willebrand factor A domains (DVWA) have been observed to be associated with osteoarthritis but have not been studied in LDD \[[@R46]-[@R49]\].

The aims of this study were to examine the allelic diversity of structural, inflammatory, matrix modifying, vitamin D receptor gene variants and variants previously associated with osteoarthritis and their association with surgical candidates and surgical patients with LDD.

SUBJECTS AND METHODS
====================

Cases and Controls
------------------

This study included 146 unrelated Norwegian patients, with chronic low back pain and disc degeneration. The age of the patients ranged from 30 to 76 years (mean = 53.2 years). Among whom, 80 were females and 66 were males and their age at the first time experience of back pain ranged from 10 to 61 years (mean \[SD\], 32.9 \[10.3\]). Patients were recruited from two randomized controlled trials (RCTs) \[[@R50],[@R51]\], a pilot study \[[@R52]\] and had been evaluated to have LBP, disc degeneration and as candidates for surgery at least 8-9 years ago. Patients had to have pain duration for at least 1 year and degeneration at L4-L5 or L5-S1, as evaluated by plain radiography and either computed tomography or magnetic resonance imaging. Among them 27 were treated conservatively, 73 had lumbar fusion and 46 underwent discectomy (Table **[1](#T1){ref-type="table"}**). The control group comprised of 188 healthy Norwegian individuals from the Norwegian Bone Marrow Donor Registry with an unknown history of back pain and age ranging from 24 to 56 years (mean = 39.3 years). Half of the controls were males and half females. Patients were asked about ethnicity, age of onset, duration of pain, family history of back pain, and smoking through a standard questionnaire. Patients were asked if they were smoking at inclusion and the number of cigarettes they smoked per day. 141 patients had one or more first degree relatives with back pain but 5 patients did not have any known family members with back pain history. All subjects received detailed written information about the study procedures and provided informed consent before their participation. The study was approved by the Regional Committee for Medical Research Ethics in Health Region South-East Norway.

Selection of Candidate Gene SNPs
--------------------------------

A total of 27 single-nucleotide polymorphisms (SNPs) from 20 different candidate genes were tested (Table **[2](#T2){ref-type="table"}**). 20 SNPs from 14 genes with a biologic relevance for disc structure, biochemistry and mechanics were selected for genotyping, based upon previously reported association with LDD in different study populations. Variants that have previously shown significant associations with different LDD phenotypes were focused. Variants of some genes that had not been found to be significantly associated, but were biologically relevant were also included. Altogether SNPs from collagen genes (COL1A1, COL2A1, COL3A1, COL9A1, COL9A2, COL9A3, COL11A1 and COL11A2), aggrecan gene (AGC1), vitamin D receptor gene (VDR), interleukin genes (IL1A, IL18R1, and IL18RAP), matrix metalloproteinase-3 gene (MMP3), and cyclooxygenase-2 gene (COX2). Furthermore, seven SNPs from six genes (PTGS2, CALM1, FZRP, DVWA and GDF5) were tested on the basis of their association reported with osteoarthritis, due to its clinical similarities to our phenotype of interest.

Genotyping
----------

Genomic DNA from 140 patients, was extracted manually from 9 ml of peripheral blood leucocytes by the salting out method \[[@R53]\] and from the remaining 6 patients, the DNA was extracted manually from 4 ml of saliva sample using the collection kit (DNA Genotek, Kanata, Ontario, Canada) following the protocol by the manufacturer. DNA quality and quantity were measured on a DNA spectrophotometer (ND-1000, NanoDrop, Wilmington USA). All the DNA samples were of good quality and quantity and had ratios within 1.8-2.0 at A260/280 and within 1.8-2.2 at A260/230. DNA from the controls was available before hand. Genotyping was performed using a Autoflex instrument and iplex kits from Sequenom^TM^ (Hamburg, Germany), at the Centre for interactive genetics; Cigene, Norwegian University of Life Sciences (UMB) Aas. 20 ng DNA was used and one negative control (water) was included with every 95 samples with variable positions, so that it served both as technical and positional control. Real-time genotype calling was followed by manual inspection and where necessary adjustment.

Statistical Analysis
--------------------

Genotype success rate, Hardy-Weinberg equilibrium (HWE), linkage disequilibrium and allelic associations were calculated using Haploview version 4.2 \[[@R54]\]. Unphased version 3.0.7 \[[@R55]\] was used to estimate haplotypes by the expectation-maximization algorithm and to test for association, as well as to calculate linkage disequilibrium. In accordance with the approach of this statistical programme for haplotype analysis, one allele was compared to a reference haplotype. Odds ratio (OR) with 95 % CI was calculated with respect to minor allele compared to major allele, using the Haldanes modification of Woolf's method \[[@R56],[@R57]\]. P-value threshold of ≤ 0.05 was chosen based upon the fact that it was a replication study of variants already reported to be significantly associated with LDD. At this threshold value, we had 80 % power to detect a genotype effect of frequency = 0.3 with an OR \> 1.9 and an allele effect of frequency = 0.4 with an OR \> 1.5. Power calculations were done in PS Power and Sample Size Calculations Version 3.0. The p-value threshold after Bonferroni correction for multiple testing was calculated to be 0.0019, as we tested 27 SNPs (0.05/27).

RESULTS
=======

The Risk of LDD is Associated with IL18R1 and IL18RAP on Chromosome 2q12
------------------------------------------------------------------------

The genotype success rate of the 27 candidate SNPs was ≥ 95 % with a mean success rate of 99.2 %. None of the selected SNPs was excluded due to technical problems with genotyping, and no divergence from Hardy-Weinberg equilibrium was observed for any of the markers (p ≥ 0.001). Allele frequencies of the 27 SNPs in both cases and controls are given in Table **[3](#T3){ref-type="table"}**. Two polymorphisms, rs2287037 from Interleukin 18 receptor 1 (IL18R1) gene and rs1420100 from Interleukin 18 receptor accessory protein (IL18RAP) gene showed a statistically non-significant association (p=0.06 and p=0.07). Both these SNPs were in HWE (p values for rs2287037 and rs1420100 were 0.51 and 0.81 respectively). Compared to the controls, there was a non-significant increase in risk of LDD for both IL18R1 (OR 1.36, 95 % CI 0.99 -- 1.87) and IL18RAP (OR 1.33 95 % CI 0.98-1.81).

The CC genotype at IL18R1 polymorphism (rs2287037) was associated (p=0.023) with LDD and was more frequent among cases (45.2%) compared to controls (33.0 %). For IL18RAP, an association was observed for the AA genotype at rs1420100 (p= 0.027). Both polymorphisms followed a recessive disease model with a risk for LDD in cases which were homozygous for risk allele (OR 1.67 \[95 % CI 1.07-2.60\] and OR 1.83 \[95% CI 1.07-3.14\], respectively).

Our associations were not statistically significant after Bonferroni correction.

Conversely the other alleles at these SNPs were negatively associated with LDD, and interestingly they were situated on a haplotype rs2287037\*T-rs1420100\*C that were less frequent in cases compared to controls (23.7 % *vs* 34.3 %, p=0.008; Table **[4](#T4){ref-type="table"}**). The linkage disequilibrium between these two alleles was modest; D\'\<0.65 and r^2^\<0.2. Hence, since carriage of non-risk allele seemed to protect against development of LDD at both loci, we tested the distribution of simultaneously carrying at least one non-risk allele at both loci and found it to reduce the risk of developing LDD (OR 0.51 \[95 % CI 0.33-0.80\]; p= 0.003).

Association of IL18RAP-IL18R1 in Non-Smokers
--------------------------------------------

Smoking is an environmental factor that has been shown to influence the risk of LDD according to some studies \[[@R58]\]. The frequency of the protective haplotype, rs2287037\*T-rs1420100\*C was lowest among the non-smoking patients (19.6 %) compared to LDD smokers (28.5 %) and controls (34.3 %). Hence the haplotype only conferred a reduced risk of LDD among non-smoking patients compared to controls (p=0.007). Cases were considered as smokers if they were smoking at inclusion. Unfortunately, smoking status was not available among controls. Significance was not reached when smokers were compared with non-smokers among LDD patients only (p=0.2).

DISCUSSION
==========

Alleles at IL18RAP (rs1420100) and IL18R1 (rs2287037) SNPs did not show a statistically significant association individually, but the tendency of association for IL18R1 (rs2287037) showed a similar trend as in a previous study (p = 0.054) by Videman *et al.*\[[@R26]\]. Homozygosity of risk alleles was associated with the risk of LDD. The non-risk alleles of two polymorphisms were negatively associated with LDD when looking at them together on a haplotype. This haplotype association might be in linkage disequilibrium with a locus involved in predisposition to LDD or it might mark several risk polymorphisms, either including or excluding those tested here in this interleukin gene cluster on chromosome 2q12.

In accordance with our findings, a study of 588 monozygotic and dizygotic male twins from the Finish population, has shown association of IL18RAP (rs1420100) with disc desiccation but not with disc height narrowing or bulging \[[@R26]\]. Videman *et al.*observed an association between individuals with AC genotype and a higher disc signal intensity, and a nearly identical association of AA and CC alleles with a lower disc signal intensity (personal communication), while we found the CC genotype to predispose to LDD. We observed haplotypic association for across IL18R1 and IL18RAP for rs2287037\*T-rs1420100\*C. As for many complex disorders, inter study heterogeneity also exists for LDD \[[@R59]\], particularly since the markers tested in studies are likely to be secondary to the causal variants and therefore inter-population differences in LD patterns will influence the single SNP association outcome. Videman *et al.*also found another polymorphism of the IL18RAP (rs917997) to be associated with disc desiccation, but no association was observed for this polymorphism in our sample. They found rs917997 to be tagging with the haplotype of IL1RL1, IL18R1, IL18RAP, and SLC9A4. This gene cluster has been shown to be associated with other inflammatory disorders, like inflammatory bowel disease \[[@R60]\], coeliac disease \[[@R61]\] and asthma. Our findings suggest that inflammation also play a role in patients with chronic LBP and disc degeneration.

IL18RAP is a subunit of IL18 receptor along with IL18R1 \[[@R62]\] and is essential for IL18 signal transduction and ligand binding affinity to IL18Rα and hence plays a functional role of regulation of both innate and adaptive immunity \[[@R63]\]. Activation of T cells and natural killer cells results in secretion of interferon gamma (IFN-γ), which in turn activates macrophages that secrete cytokines TNF-α and IL1, which are involved in increased matrix degradation both directly and through activation of proteinases and have been found to be secreted by the cells of a degenerated and herniated disc \[[@R23],[@R24],[@R64]\]. We speculate that polymorphisms of IL18RAP and IL18R1 might play a role by triggering an inflammatory response through one of the above mentioned mechanisms and hence shed light on the role of inflammation in LDD and a possible pathway for associated back pain \[[@R24]\]. While the presence of disc degeneration in many asymptomatic individual indicates an unclear relationship with back pain \[[@R65]\], high levels of cytokines like TNF-α have been found in degenerated discs where the nerve ending is exposed to enzymes and inflammatory mediators, which may explain pain in discogenic patients \[[@R66]\].

The polymorphism of IL18R1 (rs2287037) has previously also showed a tendency towards association with disc desiccation (p=0.054) in the study by Videman *et al.*\[[@R26]\]. Videman *et al.*observed an association between individuals with CC alleles and lowest disc signal intensity and TT alleles were found to be associated with higher disc signal intensity (personal communication). Our results support these finding of Videman *et al.*as in the current study the cases with CC alleles were found to be associated with LDD. To our knowledge, this is only the second time that a similar trend in association of IL18R1 polymorphism rs2287037 with LDD has been reported. The IL18R1 gene, along with four other members of the interleukin 1 receptor family (IL1R2, IL1R1, ILRL2, and IL1RL1) form a gene cluster on chromosome 2q. IL1R1 has shown to be associated with hand OA \[[@R67]\] and a genome wide linkage study have found a region of interest that could harbor genes for both LDD and OA \[[@R68]\]. Over expression of IL18 and IL18R has also been proposed to play a role in pathogenesis of rheumatoid arthritis \[[@R69]\].

We cannot exclude that our results could be false positive because of a small sample size and the fact that our associations did not withstand Bonferroni correction for multiple testing. On the other hand, the associations were with genetic variants already been reported to be associated with LDD. Hence in the future we intend to replicate our findings in a much larger European population evaluated for disc signal as well as advanced findings of LDD.

It is foremost to define a clear phenotype of disc degeneration \[[@R6]\] because this is a multi stage process progressing from decreased disc signal intensity (disc desiccation) to disc height narrowing, disc bulging, end plate degeneration and osteophytosis of facet joints \[[@R70]\]. Videman *et al.*showed association of IL18RAP and IL18R1 with an early stage of degeneration (disc desiccation). In contrast, our findings suggest associations in a patient population with severe chronic low back pain and disc degeneration, with majority had lumbar fusion and hence this group is considered to have advanced lumbar disc disease.

We however did not find any associations of other structural, matrix degrading, Vitamin D and osteoarthritic genes with advanced stage degeneration in our patients. Videman *et al.*on the other hand did find 10 such associations but most of them with an early stage of degeneration (disc desiccation) \[[@R26]\]. Inability to detect any such associations in our study could be due to limitations of small sample size, not covering all variants of the candidate genes and lack of advanced imaging (no information on disc signal intensity and disc bulging). Videman *et al.*had an enhanced ability to detect the associations with an early stage LDD, due to an accurate method of quantitative measurement of degeneration using cerebrospinal fluid adjusted disc signal intensity, which we lacked and they studied 99 variants compared to 27 in our study. This reduced our power and precision to estimate the association. The DNA from control group had been collected previously, but was not linked to information about back pain and degeneration. Although they were considered healthy at inclusion, we would expect that some of them had disc degeneration and had experienced back pain. The association of IL18RAP-IL18R1 haplotype in non smokers could also be false positive due to a small sample, lack of information on smoking status of controls and that smokers among cases were smoking at inclusion.

The proportion of LDD and its associated LBP in patients was supposed to be higher than controls because they attended the orthopedic clinic and had either undergone or were candidates for surgery. We could have enhanced our power to detect association for other genes if we compared patients with controls without any degeneration, or even better if we have had access to a larger patient cohort. The study design of Videman *et al*, on the other hand, was not case-control based. Our study had genetic homogeneity (all subjects were of homogenous Norwegian origin) \[[@R71]\], a high genotype success rate (94.9 % to 100 %), no SNP was excluded due to technical issues with genotyping and there was no deviation of any SNP from Hardy Weinberg equilibrium.

Our study is supportive of a polygenic nature of lumbar disc degeneration and suggests that variation in interleukin 18 receptor genes could affect the risk of advanced stage of disc degeneration and its associated LBP. Our findings need to be tested in a larger sample with an accurate phenotype classification.
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###### 

Demographic and Disease Characteristics Cases with Chronic Low Back Pain Given as Numbers N, Unless Stated Otherwise

  ---------------------------------------------------------------------------------------------------------- ----------------------------------------------
  Total number of cases                                                                                      146 patients with lumbar disc degeneration
  Ethnicity                                                                                                  Norwegian
  Gender (Males/Females)                                                                                     68/78
  Age (8 year follow up), years                                                                              Range: 30-76, Mean \[SD\]: 53.2 \[8.8\]
  Age of Onset, years                                                                                        Range: 10-61, Mean \[SD\]: 32.9 \[10.3\]
  Duration of pain (baseline), months                                                                        Range: 10-480, Mean \[SD\]: 128.8 \[103.04\]
  Smokers/non-smokers/unknown                                                                                68/69/9
  Surgical status (None/discectomy/lumbar fusion)                                                            27/46/73
  History of back pain in first degree relatives, with no treatment/conservative treatment/surgery/unknown   19/82/40/5
  ---------------------------------------------------------------------------------------------------------- ----------------------------------------------

###### 

Selected SNP Candidates for Lumbar Disc Degeneration

  Gene            SNP[\*](#T2F1){ref-type="table-fn"}   Chromosome   Location        Minor/Major Allele   References
  --------------- ------------------------------------- ------------ --------------- -------------------- ----------------------------------
  *AGC1*          rs1042631                             15q26.1      Exon (L2141L)   T/C                  \[[@R26]\]
  *AGC1*          rs1516797                             15q26.1      Intron          G/T                  \[[@R26]\]
  *VDR*           rs10735810                            12q13.11     Exon (M162T)    C/T                  \[[@R37]\] \[[@R70]\]
  *VDR*           rs731236                              12q13.11     Exon (I352I)    C/T                  \[[@R37]\] \[[@R70]\]
  *COL1A1*        rs2075555                             17q21.33     Intron          A/C                  \[[@R26]\] \[[@R29]\]
  *COL2A1*        rs917055                              12q13.11     Intron          T/C                  \[[@R26]\]
  *COL3A1*        rs2056156                             2q32.2       Intron          C/T                  \[[@R26]\]
  *COL9A1*        rs696990                              6q13         Intergenic      G/A                  \[[@R26]\]
  *COL9A2*        rs7533552                             1p34.2       Exon (Q326R)    G/A                  \[[@R26]\] \[[@R30]\] \[[@R31]\]
  *COL9A3*        rs61734651                            20q13.33     Exon (R103W)    C/T                  \[[@R32]\] \[[@R33]\]
  *COL11A1*       rs1463035                             1p21.1       Intron          G/A                  \[[@R26]\]
  *COL11A1*       rs1676486                             1p21.1       Exon (S1535P)   A/G                  \[[@R34]\]
  *COL11A2*       rs2072915                             6p21.32      Upstream        T/A                  \[[@R26]\]
  *IL1A*          rs2071375                             2q13         Intron          A/G                  \[[@R26]\] \[[@R42]\]
  *IL18R1*        rs2287037                             2q12.1       Upstream        A/G                  \[[@R26]\]
  *IL18RAP*       rs1420100                             2q12.1       Intron          T/G                  \[[@R26]\]
  *IL18RAP*       rs1420106                             2q12.1       Upstream        T/C                  \[[@R26]\]
  *IL18RAP*       rs917997                              2q12.1       Downstream      A/G                  \[[@R26]\]
  *MMP3*          rs72520913                            11q22.2      Upstream        -/A                  \[[@R38]\]
  *COX2(PTGS2)*   rs5277                                1q31.1       Exon (V102V)    C/G                  \[[@R43]\]
  *PTGS2(COX2)*   rs4140564                             1q31.1       Upstream        C/T                  \[[@R49]\]
  *CALM1*         rs12885713                            14q32.11     5'UTR           C/T                  \[[@R47]\]
  *DVWA*          rs11718863                            3p25.1       Exon            T/A                  \[[@R48]\]
  *DVWA*          rs7639618                             3p25.1       Exon            T/C                  \[[@R48]\]
  *FZRP*          rs288326                              2q32.1       Exon (R200W)    A/G                  \[[@R46]\]
  *FZRP*          rs7775                                2q32.1       Exon (R324G)    G/C                  \[[@R46]\]
  *GDF5*          rs143383                              20q11.22     5'UTR           C/T                  \[[@R48]\]

Single-nucleotide polymorphism.

###### 

Association Analysis of the Structural, Inflammatory, Matrix Degradative, Vitamin D Receptor and Osteoarthritis Associated Gene Variants with LDD

  SNP[\*\*\*](#T3F3){ref-type="table-fn"}   Gene            Risk Allele   RAF[\*\*](#T3F2){ref-type="table-fn"} Cases   RAF Control   OR[\*](#T3F1){ref-type="table-fn"}(95% CI)   p Value
  ----------------------------------------- --------------- ------------- --------------------------------------------- ------------- -------------------------------------------- ---------
  rs1042631                                 *AGC1*          T             0.212                                         0.176         1.27 (0.86-1.86)                             0.23
  rs1516797                                 *AGC1*          T             0.641                                         0.622         1.09 (0.79-1.50)                             0.60
  rs10735810                                *VDR*           A             0.401                                         0.370         1.14 (0.83-1.56)                             0.41
  rs731236                                  *VDR*           A             0.603                                         0.568         1.16 (0.85-1.58)                             0.35
  rs2075555                                 *COL1A1*        G             0.873                                         0.864         1.08 (0.69-1.70)                             0.74
  rs917055                                  *COL2A1*        A             0.168                                         0.168         1.00 (0.67-1.51)                             0.99
  rs2056156                                 *COL3A1*        C             0.441                                         0.420         1.09 (0.80-1.48)                             0.58
  rs696990                                  *COL9A1*        C             0.210                                         0.173         1.27 (0.86-1.87)                             0.22
  rs7533552                                 *COL9A2*        T             0.757                                         0.731         1.14 (0.80-1.63)                             0.45
  rs61734651                                *COL9A3*        C             0.942                                         0.939         1.05 (0.56-1.97)                             0.87
  rs1463035                                 *COL11A1*       T             0.810                                         0.797         1.08 (0.74-1.59)                             0.68
  rs1676486                                 *COL11A1*       A             0.229                                         0.217         1.07 (0.74-1.55)                             0.72
  rs2072915                                 *COL11A2*       T             0.731                                         0.714         1.09 (0.77-1.54)                             0.62
  rs2071375                                 *IL1A*          C             0.700                                         0.670         1.15 (0.82-1.60)                             0.42
  rs2287037                                 *IL18R1*        C             0.668                                         0.596         1.36 (0.99-1.87)                             0.06
  rs1420100                                 *IL18RAP*       A             0.493                                         0.422         1.33 (0.98-1.81)                             0.07
  rs1420106                                 *1L18RAP*       A             0.253                                         0.239         1.08 (0.76-1.54)                             0.68
  rs917997                                  *IL18RAP*       T             0.262                                         0.235         1.16 (0.81-1.65)                             0.43
  rs72520913                                *MMP3*          A             0.497                                         0.470         1.11 (0.82-1.51)                             0.50
  rs5277                                    *COX2(PTGS2)*   C             0.836                                         0.832         1.02 (0.68-1.54)                             0.91
  rs4140564                                 *PTGS2(COX2)*   A             0.949                                         0.931         1.35 (0.72-2.56)                             0.34
  rs12885713                                *CALM1*         C             0.451                                         0.406         1.20 (0.88-1.64)                             0.25
  rs11718863                                *DVWA*          A             0.842                                         0.824         1.14 (0.76-1.71)                             0.54
  rs7639618                                 *DVWA*          C             0.842                                         0.824         1.14 (0.76-1.71)                             0.54
  rs288326                                  *FZRP*          A             0.123                                         0.109         1.15 (0.72-1.84)                             0.57
  rs7775                                    *FZRP*          C             0.083                                         0.059         1.42 (0.79-2.56)                             0.24
  rs143383                                  *GDF5*          A             0.651                                         0.629         1.10 (0.79-1.52)                             0.57

Odds ratio (95 % Confidence interval)

Risk allele frequency

Single-nucleotide polymorphism.

§rs2287037, allele counts in cases: 66 CC, 63 CT, 17 TT; allele counts in controls: 62 CC, 100 CT and 26 TT.

rs1420100, allele counts in cases: 37 AA, 69 AC, 39 CC; allele counts in controls: 29 AA, 98 AC and 58 CC.

###### 

Association Analysis of Estimated Haplotypes of IL18R1 (rs2287037) and IL18RAP (rs1420100)

  Haplotype                                Cases n (%)    Controls n (%)   OR[\*\*](#T4F2){ref-type="table-fn"} (95% CI)   p Value
  ---------------------------------------- -------------- ---------------- ----------------------------------------------- ---------
  T - C                                    68.8 (23.7)    126.9 (34.3)     0.63 (0.43-0.93)                                0.008
  C -- A[\*](#T4F1){ref-type="table-fn"}   114.8 (39.6)   133.9 (36.2)     1.0                                             0.176
  C - C                                    78.2 (27.0)    87.1 (23.5)      1.05 (0.68-1.61)                                0.563
  T - A                                    28.2 (9.7)     22.1 (6.0)       1.49 (0.71-3.10)                                0.225

Reference haplotype

Odds ratio (95 % Confidence interval).
